Primary Breast Cancers are Reduced by Raloxifene

University of Pennsylvania Cancer Center
Last Modified: May 19, 1998

In a second analysis of the study presented yesterday, researchers found that the risk of developing breast cancer was reduced by 58% in women taking Raloxifene, compared to women receiving a placebo. This dramatic reduction was observed in postmenopausal women being treated for osteoporosis who had no history of breast cancer. The researchers conclude that there is substantial evidence for a profound reduction in the risk of developing breast cancer for patients taking Raloxifene.

Raloxifene has target-site specific estrogen agonist effects on bone and lipid an antagonist effects on breast and uterine tissue, via modulation an high affinity binding to the estrogen receptor on tumor cells.

[ Original Abstract ]


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Three Medications Beneficial in Breast Cancer Prevention

Nov 27, 2015

But benefits need to be weighed against increased risk of clots, endometrial cancer, stroke

Tamoxifen Recommended to Reduce Breast Cancer Risk

Nov 27, 2015

Also, treatment of metastatic breast cancer with a new form of paclitaxel improves survival

USPSTF: Offer Breast CA Risk-Reducing Rx to High-Risk Patients

Sep 24, 2013

Tamoxifen, raloxifene recommended for women with raised risk, low risk of adverse meds effects